RETRACTED: Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson’s disease in rat model? (Human & Experimental Toxicology, (2014), 33, 12, (1217-1231), 10.1177/0960327114524238);Do adipose tissue-derived mesenchymal stem cells ameliorate Parkinson's disease in rat model?

Human and Experimental Toxicology

Volumn 33, Issue 12, 2014, Pages 1217-1231

  Ahmed, H H ^a   Salem, A M ^b   Atta, H M ^c   Ghazy, M A ^b   Aglan, H A ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b Ain Shams University   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

adipose tissue derived mesenchymal stem cells; anti inflammatory activity; immunomodulatory effect; neurotrophic capacity; Parkinson's disease

Indexed keywords

BETA1 INTEGRIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBIDOPA PLUS LEVODOPA; CD14 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CEREBROLYSIN; DOPAMINE; HERMES ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; ROTENONE; TRANSFORMING GROWTH FACTOR BETA; TYROSINE 3 MONOOXYGENASE; VASCULAR CELL ADHESION MOLECULE 1; AMINO ACID; CARBIDOPA; CARBIDOPA, LEVODOPA DRUG COMBINATION; CCL2 PROTEIN, RAT; DRUG COMBINATION; LEUKOCYTE ANTIGEN; LEVODOPA;

ADIPOGENESIS; ADIPOSE DERIVED STEM CELL; ADIPOSE TISSUE; ADULT; AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BRAIN TISSUE; CELL DIFFERENTIATION; CELL STRUCTURE; CHONDROGENESIS; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROMETRY; GENE EXPRESSION; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OMENTUM; OVARIECTOMY; PARKINSON DISEASE; PROTEIN BLOOD LEVEL; RAT; RAT MODEL; REAL TIME POLYMERASE CHAIN REACTION; SRY GENE; ANIMAL; BLOOD; BRAIN; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

ADIPOSE TISSUE; AMINO ACIDS; ANIMALS; ANTIGENS, CD; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CARBIDOPA; CELL DIFFERENTIATION; CELLS, CULTURED; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; FEMALE; GENE EXPRESSION; GENES, SRY; LEVODOPA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OVARIECTOMY; PARKINSON DISEASE; RATS, SPRAGUE-DAWLEY; ROTENONE; TRANSFORMING GROWTH FACTOR BETA; TYROSINE 3-MONOOXYGENASE;

EID: 84919691783     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327117716821     Document Type: Erratum

References (96)

1. Braak H, Tredici KD, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003 ; 24: 197-211
2. Wijeyekoon R, Barker RA. Cell replacement therapy for Parkinson's disease. Biochim Biophys Acta. 2009 ; 1792 (7). 688-702
3. Diamond SG, Markham CH, Hoehn MM, et al. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology. 1990 ; 40: 763-766
4. Becker JB. Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav. 1999 ; 64: 803-812
5. Priyadarshi A, Khuder SA, Schaub EA, et al. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res. 2001 ; 86: 122-127
6. Herishanu YO, Medvedovski M, Goldsmith JR, et al. A case-control study of Parkinson's disease in an urban population of southern Israel. Can J Neurol Sci. 2001 ; 28: 144-147
7. Hisata J. Final supplemental environmental impact statement. Lake and stream rehabilitation: rotenone use and health risks. Washington State Department of Fish and Wildlife: ; 2002 :
8. Talpade DJ, Greene JG, Higgins DS, et al. In vivo labeling of mitochondrial complex I (NADH: ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone. J Neurochem. 2000 ; 75: 2611-2621
9. Sherer TB, Kim JH, Betarbet R, et al. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol. 2003 ; 179: 9-16
10. Eckert A, Keil U, Marques CA, et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol. 2003 ; 66: 1627-1634
11. Gao H, Hong J, Zhang W, et al. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci. 2002 ; 22 (3). 782-790
12. Abdel-Salam OM. Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 ; 7: 321-342
13. Riley C, Hutter Paier B, Windisch M, et al. A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication. J Neural Transm. 2006 ; 113: 103-110
14. Lukhanina EP, Karaban' IN, Burenok IuA, et al. Effect of cerebrolysin on the electroencephalographic indices of brain activity in Parkinson's disease. Zh Nevrol Psikhiatr Im S S Korsakova. 2004 ; 104: 54-60
15. Correia AS, Anisimov SV, Li JY, et al. Stem cell-based therapy for Parkinson's disease. Annal Med. 2005 ; 37: 487-498
16. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol. 2007 ; 211: 27-35
17. Lee OK, Kuo TK, Chen WM, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood. 2004 ; 103: 1669-1675
18. Ankrum J, Karp JM. Mesenchymal stem cell therapy: two steps forward, one step back. Trend Mol Med. 2010 ; 16 (5). 203-209
19. Sowa Y, Imura T, Numajiri T, et al. Adipose-derived stem cells produce factors enhancing peripheral nerve regeneration: influence of age and anatomic site of origin. Stem Cell Dev. 2012 ; 21: 1852-1862
20. Taha MF, Hedayati V. Isolation, identification and multipotential differentiation of mouse adipose tissue-derived stem cells. Tissue Cell. 2010 ; 42: 211-216
21. Levi B, James AW, Nelson ER, et al. Human adipose derived stromal cells heal critical size mouse calvarial defects. PLoS One. 2010 ; 5: e11177
22. Tomiyama K, Murase N, Stolz DB, et al. Characterization of transplanted GFP+ bone marrow cells into adipose tissue. Stem Cells. 2008 ; 26: 330-338
23. Alhadlaq A, Mao JJ. Mesenchymal stem cells: isolation and therapeutics. Stem Cells Dev. 2004 ; 13: 436-448
24. Rombouts WJ, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia. 2003 ; 17: 160-170
25. Peister A, Mellad JA, Larson BL, et al. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation and differentiation potential. Blood. 2004 ; 103: 1662-1668
26. Phinney DG, Kopen G, Isaacson RL, et al. Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth and differentiation. J Cell Biochem. 1999 ; 72: 570-585
27. Schäfer S, Calas A, Vergouts M, et al. Immunomodulatory influence of bone marrow-derived mesenchymal stem cells on neuroinflammation in astrocyte cultures. J Neuroimmunol. 2012 ; 249: 40-48
28. Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells. 2004 ; 22: 1330-1337
29. Qin H, Zhao L, Sun J, et al. The differentiation of mesenchymal stem cells into inner ear hair cell-like cells in vitro. Acta Oto-Laryngol. 2011 ; 131: 1136-1141
30. Muñoz-Fernández R, Blanco FJ, Frecha C, et al. Follicular dendritic cells are related to bone marrow stromal cell progenitors and to myofibroblasts. J Immunol. 2006 ; 177: 280-289
31. Lau HY, Bhatia M. Effect of CP-96,345 on the expression of adhesion molecules in acute pancreatitis in mice. Am J Physiol Gastrointes Liver Physiol. 2007 ; 292: 1283-1292
32. Official Methods of Analysis. 16 th ed. Washington DC: Association of Official Analysis, 1995. Washington DC: Association of Official Analysis ; 1995 :
33. Antkiewicz-Michaluk L, Karolewicz B, Romańska I, et al. 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur J Pharmacol. 2003 ; 466: 263-269
34. Lindner MD, Winn SR, Baetge EE, et al. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and Parkinsonian symptoms. Exp Neurol. 1996 ; 132: 62-76
35. Barnes JM, Paget GE. Mechanisms of toxic action. Prog Med Chem. 1965 ; 4: 18-38
36. Alvarez A, Laredo M, Varela M, et al. P2-402: Double-blind, placebo-controlled study of three different dosage of cerebrolysin in patients with mild to moderate Alzheimer's disease. Alzheimer's Dement. 2006 ; S364: 2
37. Zhao DC, Lei JX, Chen R, et al. Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. World J Gastroentrol. 2005 ; 14: 3431-3440
38. Schermer S The blood morphology of laboratory animals. 3 rd ed. Philadelphia, PA: F.A. Davi, 1967, p 42. Philadelphia, PA: F.A. Davi ; 1967: 42.
39. Sambrook L, Fritsch EF, Manitatis T Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Press ; 1989 :
40. An J, Beauchemin N, Albanese J, et al. Use of a rat cDNA probe specific for the Y chromosome to detect male-derived cells. J Androl. 1997 ; 18: 289-293
41. Kropf J, Schurek JO, Wollner A, et al. Methodological aspects of the immunological measurement of transforming growth factor-beta 1 (TGF-β1) in blood. Clin Chem. 1997 ; 43: 1965-1974
42. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Ann Rev Immunol. 1997 ; 15: 675-705
43. Laske C, Stransky E, Eschweiler GW, et al. Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J Psych Res. 2007 ; 41: 600-605
44. Ciarlone EA. Determination of catecholamines spectrophotofluro-metrically. Am J Physiol. 1978 ; 125: 731-737
45. Ali FKh, El-Shafai SA, Samhan FA, et al. Effect of water pollution on expression of immune response genes of Solea aegyptiaca in Lake Qarun. Afr J Biotechnol. 2008 ; 7: 1418-1425
46. Bouchez G, Sensebé L, Vourc'h P, et al. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Neurochem Int. 2008 ; 52: 1332-1342
47. Gaytan F, Barreiro ML, Caminos JE, et al. Expression of ghrelin and its functional receptor, the type 1a growth hormone secretagogue receptor, in normal human testis and testicular tumors. J Clin Endocrinol Metabol. 2004 ; 89: 400-409
48. Armitage P, Berry G. Statistical method in medical research. 2 nd ed. Oxford, UK: Blockwell Significant Publication, 1987, pp. 186-213. Oxford, UK: Blockwell Significant Publication ; 1987: 186-213.
49. Glavaski-Joksimovic A, Bohn MC. Mesenchymal stem cells and neuroregeneration in Parkinson's disease. Exp Neurol. 2013 ; 247: 25-38
50. Rochefort GY, Vaudin P, Bonnet N, et al. Influence of hypoxia on the domiciliation of mesenchymal stem cells after infusion into rats: possibilities of targeting pulmonary artery remodeling via cells therapies?. Respir Res. 2005 ; 6: 125
51. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult mesenchymal stem cells. Science. 1999 ; 284: 143-147
52. Li DF, Yang C, Li Z, et al. Immunophenotypic comparison of adipose-derived mesenchymal stem cells from the greater omentums and subcutaneous adipose tissues of rats. Nan Fang Yi Ke Da Xue Xue Bao. 2010 2262 ; 30 (10). 2256-2258
53. Ren ZW, Zhao Z, Wang Y, et al. Study on differentiation of rat adipose tissue-derived stromal cells into Schwann-like cells. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2011 ; 27 (4). 385-388
54. Ying C, Hu W, Cheng B, et al. Neural differentiation of rat adipose-derived stem cells in vitro. Cell Mol Neurobiol. 2012 ; 32 (8). 1255-1263
55. Sachs PC, Francis MP, Zhao M, et al. Defining essential stem cell characteristics in adipose-derived stromal cells extracted from distinct anatomical sites. Cell Tiss Res. 2012 ; 349 (2). 505-515
56. Ji JF, He BP, Dheen ST, et al. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells. 2004 ; 22: 415-427
57. Steingen C, Brenig F, Baumgartner L, et al. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J Mol Cell Cardiol. 2008 ; 44: 1072-1084
58. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors. 1993 ; 8: 1-9
59. Unsicker K, Strelau J. Functions of transforming growth factor-beta isoforms in the nervous system. Cues based on localization and experimental in vitro and in vivo evidence. Eur J Biochem. 2000 ; 267: 6972-6975
60. Rota E, Bellone G, Rocca P, et al. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol Sci. 2006 ; 27: 33-39
61. Cunningham C, Boche D, Perry VH. Transforming growth factor beta1, the dominant cytokine in murine prion disease: influence on inflammatory cytokine synthesis and alteration of vascular extracellular matrix. Neuropathol Appl Neurobiol. 2002 ; 2: 107-119
62. Banks WA, Farr SA, Morley JE. Entry of blood-bone cytokines into the central nervous system: effects on cognitive processes. Neuroimmunomodulation. 2002 ; 3: 319-327
63. Banisadr G, Gosselin RD, Mechighel P, et al. Highly regionalized neuronal expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) in rat brain: evidence for its colocalization with neurotransmitters and neuropeptides. J Compar Neurol. 2005 ; 489: 275-292
64. Reale M, Iarlori C, Thomas A, et al. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun. 2009 ; 23: 55-63
65. Kalkonde YV, Morgan WW, Sigala J, et al. Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration. Brain Res. 2007 ; 1128: 1-11
66. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012 ; 20: 14-20
67. Kim YJ, Park HJ, Lee G, et al. Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action. Glia. 2009 ; 57: 13-23
68. Kim HJ, Lee JH, Kim SH. Therapeutic effects of human mesenchymal stem cells on traumatic brain injury in rats: secretion of neurotrophic factors and inhibition of apoptosis. J Neurotrauma. 2010 ; 27: 131-138
69. Becker KJ. Modulation of the postischemic immune response to improve stroke outcome. Stroke. 2010 ; 41: S75 - S78
70. Wahl SM, Hunt DA, Wakefield LM, et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA. 1987 ; 84: 5788-5792
71. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Ann Rev Immunol. 2006 ; 24: 99-146
72. Dohgu S, Yamauchi A, Takata F, et al. Transforming growth factor-beta1 upregulates the tight junction and P-glycoprotein of brain microvascular endothelial cells. Cell Mol Neurobiol. 2004 ; 24: 491-497
73. Yoo S, Chang D, Lee H, et al. Immune following suppression mesenchymal stem cell transplantation in the ischemic brain is mediated by TGF-β. Neurobiol Dis. 2013 ; 58: 249-257
74. Shyy JY, Li YS, Lin MC, et al. Multiple cis-elements mediate shear stress-induced gene expression. J Biomech. 1995 ; 28: 1451-1457
75. Feinberg MW, Shimizu K, Lebedeva M, et al. Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation. Circ Res. 2004 ; 94: 601-608
76. Gulcin I. Comparison of in vitro antioxidant and antiradical activities of l-tyrosine and l-dopa. Amino Acids. 2007 ; 32: 431-438
77. Kim SU, Park YH, Min JS, et al. Peroxiredoxin I is a ROS/p38 MAPK-dependent inducible antioxidant that regulates NF-κB-mediated iNOS induction and microglial activation. J Neuroimmunol. 2013 ; 259 ((1-2)). 26-36
78. Alvarez XA, Lombardi VR, Fernández-Novoa L, et al. Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection. J Neural Transm. 2000 ; 59: 281-292
79. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol. 2001 ; 63: 71-124
80. Tsukahara T, Takeda M, Shimohama S, et al. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery. 1995 ; 37: 733-739
81. Meredith GE, Callen S, Scheuer DA. Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res. 2002 ; 949: 218-227
82. Williams SN, Undieh AS. Dopamine D1-like receptor activation induces brain-derived neurotrophic factor protein expression. NeuroReport. 2009 ; 20: 606-610
83. O'Byrne MB, Bolam JP, Hanley JJ, et al. Tyrosine-hydroxylase immunoreactive cells in the rat striatum following treatment with MPP. Adv Exp Med Biol. 2000 ; 483: 369-374
84. Bousquet M, St-Amour I, Vandal M, et al. High-fat diet exacerbates MPTP-induced dopaminergic degeneration in mice. Neurobiol Dis. 2012 ; 45: 529-538
85. Greenamyre JT, MacKenzie GM, Peng TI, et al. Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp. 1999 ; 66: 85-97
86. Lattanzi W, Geloso MC, Saulnier N, et al. Neurotrophic features of human adipose tissue derived stromal cells: in vitro and in vivo studies. J Biomed Biotechnol. 2011 ; 2011: 468705
87. Chadi G, Moller A, Rosen L, et al. Protective actions of human recombinant basic fibroblast growth factor on MPTP-lesioned nigrostriatal dopamine neurons after intraventricular infusion. Exp Brain Res. 1993 ; 97: 145-158
88. Jin GZ, Cho SJ, Choi EG, et al. Rat mesenchymal stem cells increase tyrosine hydroxylase expression and dopamine content in ventral mesencephalic cells in vitro. Cell Biol Int. 2008 ; 32: 1433-1438
89. Bahat-Stroomza M, Barhum Y, Levy YS, et al. Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease. J Mol Neurosci. 2009 ; 39: 199-210
90. Zhang X, Andren PE, Svenningsson P. Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease. Brain Res. 2006 ; 1095 (1). 207-210
91. Xie L, Hu LF, Teo XQ, et al. Therapeutic effect of hydrogen sulfide-releasing l-dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat model. PLoS One. 2013 ; 8 (4). e60200
92. Fleming SM, Delville Y, Schallert T. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of sinemet and protective effects of methylphenidate. Behav Brain Res. 2005 ; 156: 201-213
93. Selianina NV, Karakulova IUV. The effect of neurotrophic treatment on the activation of reparative processes in patients with acute traumatic brain injury. Zhurnal Nevrologii i Psikhiatrii Imeni S. S. Korsakova. 2012 ; 112 (5). 46-49
94. Georgy GS, Nassar NN, Mansour HA, et al. Cerebrolysin ameloriates cognitive deficits in type III diabetic rats. PLoS One. 2013 ; 8 (6). e64847
95. Hartbauer M, Hutter-Paier B, Skofitsch G, et al. Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Trans. 2001 ; 108 (4). 459-473
96. Fukuchi M, Fujii H, Takachi H, et al. Activation of tyrosine hydroxylase (TH) gene transcription induced by brain-derived neurotrophic factor (BDNF) and its selective inhibition through Ca(2+) signals evoked via the N-methyl-d-aspartate (NMDA) receptor. Brain Res. 2010 ; 1366: 18-26